Mutations of the <i>PTPN11</i> and <i>RAS</i> genes in rhabdomyosarcoma and pediatric hematological malignancies

Yuyan Chen, Junko Takita, Mitsuteru Hiwatari, +8

Genes Chromosomes and Cancer

Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma

Jessica Okubo, Junko Takita, Yuyan Chen, +8

Oncogene

MedicineReceptor Tyrosine KinasePathologyForm Alk ProteinAberrant Activation +4

Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets

Masahiro Sekiguchi, Masafumi Seki, Tomoko Kawai, +38

npj Precision Oncology

Fusion of an AF4-related gene, LAF4, to MLL in childhood acute lymphoblastic leukemia with t(2;11)(q11;q23)

Mitsuteru Hiwatari, Tomohiko Taki, Takeshi Taketani, +6

Oncogene

Hematological MalignancyLymphoid NeoplasiaMedicineMixed-phenotype Acute LeukemiaImmunology +6

Disease Progression of WHIM Syndrome in an International Cohort of 66 Pediatric and Adult Patients

Christoph B. Geier, Maryssa Ellison, Rachel Cruz, +80

Journal of Clinical Immunology

Advanced-stage gastrointestinal stromal tumor treated with imatinib in a 12-year-old girl with a unique mutation of PDGFRA

Minoru Kuroiwa, Mitsuteru Hiwatari, Junko Hirato, +6

Journal of Pediatric Surgery

Gastrointestinal OncologyMalignant DiseaseMedicinePathologyGastrointestinal Stromal Tumors +5

Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia

Tomoya Isobe, Masatoshi Takagi, Aiko Sato‐Otsubo, +54

Nature Communications

EngineeringMixed-phenotype Acute LeukemiaGeneticsPathologyMultiomics +24

Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis

Kumiko Uryu, Riki Nishimura, Keisuke Kataoka, +23

Oncotarget

Targeted inactivation of nuclear interaction partner of ALK disrupts meiotic prophase

Anna Lena Illert, Hiroyuki Kawaguchi, Cristina Antinozzi, +9

Development

Comprehensive genetic analysis of pediatric germ cell tumors identifies potential drug targets

Yasuo Kubota, Masafumi Seki, Tomoko Kawai, +21

Communications Biology